500 Milliliter Flasks on a White Background.

OUR SCIENCE IMPACTS LIVES

Science and innovation are the lifeblood of our company. But we’re doing more than developing medicines that perform well in the lab—we’re elevating the current standard of care to bring greater benefits to our patients. 

Published 1,150+ papers

 

AbbVie scientists in the medical research community published more than 1,150 papers
in 2019 -  allowing others to build on scientific knowledge we’ve developed.

26*

different medical compounds in 86 different currently being investigated
in clinical studies across the UK

*Data as of Jan 2021

2,263**

patients participating in an AbbVie clinical trials in the UK

*Data as of Dec 2020

Over £11.5 million

was invested in UK Clinical trial activity throughout 2019

Over £50 million

has been invested in Clinical Trial activity in the UK since 2014

THERAPEUTIC FOCUS AREAS

Researching Areas of Unmet Medical Need

We’re constantly finding new ways to address patients’ most serious health issues. We concentrate our efforts on a core set of therapeutic areas—ones where we’ve proven our expertise, and where we feel we can have an even greater impact on disease and how it is managed.

Where We Operate

14 countries with manufacturing and R&D facilities.

Drug Development Process

From discovery to clinical trials to regulatory approval, learn more about the journey to bring a new therapy to patients.

A close up female scientist wearing goggles and building a prototype.
Technologies and Platforms

Bringing Better Solutions to Patients

By investing in groundbreaking technologies and platforms, our goal is to drive innovation within our pipeline and deliver better solutions to patients.

$5b*

invested to advance science

*Excluding specified items

72%

of medicines in our pipeline are considered first-in-kind

~16k

scientists working globally to make a difference

Discovering and developing therapies that have the potential to transform the standard of care for people battling serious and often life-threatening illnesses is our core mission.

Michael Severino, M.D, Executive Vice President, R&D and Chief Scientific Officer